Evidence map›Paper›PMID 37769219›Full record

ArticleJCO global oncology2023

Clinicopathologic Profile and Psychosocial Experiences of Nigerian Breast Cancer Survivors.

Funmilola Olanike Wuraola, Olalekan Olasehinde, Matteo Di Bernardo, Adewale Abdulwasiu Aderounmu, Adewale Oluseye Adisa, Oluwatosin Zaniab Omoyiola, Adeleye Dorcas Omisore, Thomas Peter Kingham, Victoria Mango, Olusegun Isaac Alatise

Open access · goldAbstract read
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Funmilola Olanike WuraolaSurgery Department, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0003-3315-990X
Olalekan OlasehindeSurgery Department, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0002-8706-0756
Matteo Di BernardoMassachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0002-7574-1941
Adewale Abdulwasiu AderounmuSurgery Department, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.ORCID 0000-0003-0142-7818
Adewale Oluseye AdisaSurgery Department, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0003-1927-3992
Oluwatosin Zaniab OmoyiolaMorbid Anatomy and Forensic Medicine Department, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.ORCID 0000-0002-9756-3007
Adeleye Dorcas OmisoreRadiology Department, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0002-5660-6242
Thomas Peter KinghamMemorial Sloan Kettering Cancer Centre, New York, NY.
Victoria MangoMemorial Sloan Kettering Cancer Centre, New York, NY.ORCID 0000-0002-1844-7965
Olusegun Isaac AlatiseSurgery Department, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0002-0565-077X
Obafemi Awolowo University Teaching Hospitals Complex · NGMemorial Sloan Kettering Cancer Center · USMassachusetts Institute of Technology · USObafemi Awolowo University · NG

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeBreast cancer survivors are a distinct category of patients with unique characteristics and needs. The population of survivors is expected to increase, given the rising incidence of breast cancer in Nigeria, and the improvements in breast cancer outcomes. This study evaluated the clinicopathologic characteristics and the psychosocial experiences of a cohort of Nigerian breast cancer survivors.

methodsFrom an institutional breast cancer database, patients managed between January 2010 and December 2016 were evaluated. Clinicopathologic characteristics, treatment details, and survival estimates were assessed. These were compared with nonsurvivors managed during the same period. Survivors were defined as those who have been alive for at least 5 years from the date of presentation. Qualitatively, a purposive sample of 20 survivors was evaluated using one-on-one in-depth interviews to assess their experiences and coping mechanisms after treatment.

resultsOf the 355 patients in the database during the study period, there were 163 survivors (45.9%), while 192 (54.1%) died. Age, stage at presentation, tumor size, and receipt of multiple treatment modalities were significantly associated with survival. Five themes were identified in qualitative analysis: initial reaction to the diagnosis, experiences during treatment, social support, coping strategies, and advocacy. Strong family support and spirituality were prominent coping strategies identified in this cohort.

conclusionDespite obvious infrastructural and manpower limitations, Nigerian patients who present early and receive multimodal therapy and different breast cancer treatments have better odds of survival. Survivors have some unmet psychosocial and physical needs requiring intervention.

Indexed as

Breast NeoplasmsCancer SurvivorsAdaptation, PsychologicalFemaleHumansSocial SupportSurvivors

Identifiers

PMID37769219
PMCPMC10581652
OpenAlexW4387142672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.